HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Clinical trials for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted radiation therapy shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors like pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see if it …
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New radioactive drug targets multiple advanced cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:52 UTC